Anakinra, a recombinant IL-1Ra, blocking the binding of IL-1 to IL-1 receptor, is under clinical investigation for the treatment of metastatic cancers (ClinicalTrials.gov Identifier: NCT00072111). The gene discussed is IL1B; the disease is metastatic malignant neoplasm.